Wockhardt launches $40m manufacturing plant in Dubai

At the launch event, Murtaza Khorakiwala, Managing Director of Wockhardt, remarked: "This antibiotic works on organisms that have built resistance to antibiotics, so in a way, this will satisfy an unmet medical need."

The facility will cover more than 10,000 square metres and is designed to be self-sufficient in manufacturing operations, product testing and stability, and handling warehousing.

Wockhardt is pursuing regulatory approval for the new site; commercial production is currently expected to start in two years.

The company has another four such products which will be manufactured at the facility. Dr Habil Khorakiwala, Founder Chairman at the company, also added: "With Wockhardt’s commitment to R&D, we have five breakthrough NCEs that have been accorded Qualified Infectious Disease Product (QIDP) status by US FDA. With the new facility in the Middle East, we aim to focus on our commitment in developing medicines that can fight antimicrobial resistance."

-----------------------------------------------------------------------------------------------------------------------------------------------

Editor's Note:

To apply for becoming a contributor of en-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.